Merck announced the enrollment of first patient into new Phase III study in...
• The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation • Study aims to recruit 946 patients across 17 European countries Darmstadt, Germany,...
View ArticleMerck clarifies that it will keep its consumer health business
• Darmstadt-based company holds global rights to the name Merck with exception of the U.S. and Canada Darmstadt, Germany, 7-5-2014 — /EuropaWire/ — Merck, the supplier of top-quality high-tech...
View ArticleMerck’s acquisition of Sigma-Aldrich approved by the European Commission...
BRUSSELS, 18-6-2015 — /EuropaWire/ — The European Commission has approved the proposed acquisition of Sigma-Aldrich by Merck under the EU Merger Regulation. Both companies are active world-wide in the...
View ArticleMerck extends partnership with Weizmann Institute of Science on research...
Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot,...
View ArticleMerck CEO and Chairman of the Executive Board honoured with Weizmann Award in...
Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, announced that the Weizmann Institute, Rehovot, Israel, conferred the renowned...
View ArticleMerck receives global marketing and commercialization rights for Progyny’s...
Merck obtains global marketing and commercialization rights for the innovative Progyny Eeva® software offering, aiming to provide customers worldwide with innovative fertility technologies solutions...
View ArticleMerck to support the advancement of medical science in the field of fertility...
Investment reflects company’s commitment to innovation in fertility research Globally, six projects receive funding from this grant cycle Darmstadt, Germany, 07-Jul-2016 — /EuropaWire/ — Merck, a...
View ArticleOvarian Cancer: Merck, Pfizer initiate Phase III study JAVELIN Ovarian 100
First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending...
View ArticleMerck: Results of the ADDRESS II Phase IIb multicenter study on atacicept in...
Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L) DARMSTADT, 15-Nov-2016 — /EuropaWire/ —...
View ArticleMerck presented new data on efficacy and safety for investigational...
Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/ — Merck, a leading science and technology...
View ArticleWorld MS Day 2017: Merck launches multiple sclerosis (MS) care partner survey...
Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help...
View ArticleMerck invests EUR 90 million in four sites in Germany, Switzerland and France
Relocations to drive focus on sites in Darmstadt, Schnelldorf (Germany), Buchs (Switzerland) and Molsheim (France) Sequential implementation until the end of 2022 € 90 million investment. Net impact...
View ArticleMerck announced the enrollment of first patient into new Phase III study in...
• The ESPART* Phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation • Study aims to recruit 946 patients across 17 European countries Darmstadt, Germany,...
View ArticleMerck clarifies that it will keep its consumer health business
• Darmstadt-based company holds global rights to the name Merck with exception of the U.S. and Canada Darmstadt, Germany, 7-5-2014 — /EuropaWire/ — Merck, the supplier of top-quality high-tech...
View ArticleMerck’s acquisition of Sigma-Aldrich approved by the European Commission...
BRUSSELS, 18-6-2015 — /EuropaWire/ — The European Commission has approved the proposed acquisition of Sigma-Aldrich by Merck under the EU Merger Regulation. Both companies are active world-wide in the...
View ArticleClik here to view.
Merck extends partnership with Weizmann Institute of Science on research...
Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, today extended the partnership with Weizmann Institute of Science, Rehovot,...
View ArticleClik here to view.
Merck CEO and Chairman of the Executive Board honoured with Weizmann Award in...
Darmstadt, Germany, and Rehovot, Israel, 18-Feb-2016 — /EuropaWire/ — Merck, a leading science and technology company, announced that the Weizmann Institute, Rehovot, Israel, conferred the renowned...
View ArticleMerck receives global marketing and commercialization rights for Progyny’s...
Merck obtains global marketing and commercialization rights for the innovative Progyny Eeva® software offering, aiming to provide customers worldwide with innovative fertility technologies solutions...
View ArticleMerck to support the advancement of medical science in the field of fertility...
Investment reflects company’s commitment to innovation in fertility research Globally, six projects receive funding from this grant cycle Darmstadt, Germany, 07-Jul-2016 — /EuropaWire/ — Merck, a...
View ArticleOvarian Cancer: Merck, Pfizer initiate Phase III study JAVELIN Ovarian 100
First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending...
View Article